Karen gained her PhD in Biochemistry in 1999 at King’s College London. Following clinical operational roles at Parexel International and Napp Pharmaceuticals, Karen joined AstraZeneca where she was Associate Director of Study Management and Global Clinical Trial Leader for a number of first time in man and early phase studies.

More recently Karen was the Clinical Operations Director at Kesios Therapeutics, a biotech company spun-out of Imperial College London focused on multiple myeloma, where she was responsible for all aspects of clinical planning and delivery.